Form 4: NEOGENOMICS Director Michael Kelly Reports Significant Equity Changes Including RSU Vesting and New Option Grants

NEOGENOMICS Director Michael Aaron Kelly reported the vesting of 12,254 restricted stock units and the acquisition of new stock options and restricted stock units on June 1, 2025, increasing his direct and indirect beneficial ownership in the company.

Summary

• Michael Aaron Kelly, a Director of NEOGENOMICS INC (NEO), reported changes in his beneficial ownership of company securities.
• On June 1, 2025, 12,254 restricted stock units (RSUs) vested, converting into common stock. These RSUs were previously reported.
• Following this transaction, Mr. Kelly directly owns 44,009 shares of common stock and indirectly owns 5,000 shares through the Michael and Bonnie Kelly Revocable Trust DTD 05/02/2016.
• He also acquired 16,107 new stock options with an exercise price of $7.28, exercisable from June 1, 2026, and expiring on June 1, 2035.
• Additionally, Mr. Kelly acquired 23,077 new restricted stock units (RSUs) with a $0 exercise price, exercisable from June 1, 2026, which are not subject to expiration once vested.
• Mr. Kelly holds several other stock options with various exercise prices and expiration dates, including 2,223 options at $37.53, 3,714 options at $40.90, 13,882 options at $8.10, 8,353 options at $14.82, and 8,672 options at $13.71.

Sentiment

Score: 6

Explanation: The document is a routine Form 4 filing reporting insider equity transactions. It's neutral in terms of company performance but reflects standard compensation practices and continued insider ownership, which is generally positive for alignment.

Positives

• Director Michael Kelly's increased direct ownership of common stock (44,009 shares) and indirect ownership (5,000 shares) following the vesting of RSUs indicates continued alignment with shareholder interests.
• The grant of new stock options and restricted stock units to a director is a common form of executive compensation, aligning management incentives with long-term company performance.

Future Outlook

The document primarily reports past transactions and future vesting/expiration dates of equity awards, rather than providing a forward-looking business outlook. The new equity grants indicate a continued compensation structure for the director.

Industry Context

This Form 4 filing reflects routine insider equity transactions, common across all industries for publicly traded companies. The grant of restricted stock units and stock options is a standard practice for compensating directors and aligning their interests with long-term company performance, particularly in the biotechnology and diagnostics sector where long-term R&D cycles are common.

Comparison to Industry Standards

• The equity compensation structure, involving restricted stock units and stock options, is a standard practice for director compensation in the U.S. public markets, including the healthcare and diagnostics industry.
• Companies like Quest Diagnostics (DGX) and Laboratory Corporation of America Holdings (LH) also utilize similar equity-based incentives for their executives and directors to align their interests with company performance and shareholder returns.
• The specific number of shares and options granted would typically be benchmarked against peer companies of similar size and complexity within the diagnostic testing sector, though this document does not provide such comparative data.

Related Party Transactions

• The indirect ownership of 5,000 shares through the Michael and Bonnie Kelly Revocable Trust DTD 05/02/2016 could be considered a related party transaction, as it involves a trust associated with the reporting person and their spouse.

Stakeholder Impact

• Shareholders: The vesting of RSUs and grant of new equity awards to a director aligns the director's interests with shareholders, potentially encouraging long-term value creation. Dilution from new equity grants is a minor consideration.
• Employees: No direct impact on general employees is indicated.

Next Steps

• Future vesting of 16,107 stock options and 23,077 restricted stock units on June 1, 2026.
• Expiration of various stock options on their respective dates (e.g., May 28, 2027, June 1, 2035).

Key Dates

Recommendation

Keywords

NEOGENOMICS INC, NEO, SEC Form 4, Insider Trading, Beneficial Ownership, Restricted Stock Units, Stock Options, Director Compensation, Equity Grant, Michael Aaron Kelly